menu search

ASLN / ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis

ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis
SAN MATEO, Calif. and SINGAPORE, July 05, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, will host a webcast to discuss the topline data from the global Phase 2b TREK-AD trial of eblasakimab in patients with moderate-to-severe atopic dermatitis on July 6, 2023, at 8:30 am ET. Management will host a question and answer session following the formal presentation. Read More
Posted: Jul 5 2023, 16:30
Author Name: GlobeNewsWire
Views: 112337

ASLN News  

ASLAN (ASLN) Down 25% on Mixed Results From Skin Disease Study

By Zacks Investment Research
July 7, 2023

ASLAN (ASLN) Down 25% on Mixed Results From Skin Disease Study

ASLAN (ASLN) reports mixed results from a mid-stage study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis. The stock price more_horizontal

Aslan Pharmaceuticals shares slide amid new data on atopic dermatitis treatment

By Market Watch
July 6, 2023

Aslan Pharmaceuticals shares slide amid new data on atopic dermatitis treatment

Shares of Aslan Pharmaceuticals ASLN were down 32% premarket on Thursday after the company released new data from a clinical study of eblasakimab, an more_horizontal

ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis

By GlobeNewsWire
July 5, 2023

ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis

SAN MATEO, Calif. and SINGAPORE, July 05, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-foc more_horizontal

Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?

By Zacks Investment Research
April 5, 2023

Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?

Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Atreca, Inc. (BCEL) have performed compared to their sector so far this year. more_horizontal

Bears are Losing Control Over ASLAN Pharmaceuticals Ltd. (ASLN), Here's Why It's a 'Buy' Now

By Zacks Investment Research
March 9, 2023

Bears are Losing Control Over ASLAN Pharmaceuticals Ltd. (ASLN), Here's Why It's a 'Buy' Now

ASLAN Pharmaceuticals Ltd. (ASLN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. more_horizontal

Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?

By Zacks Investment Research
March 2, 2023

Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?

Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Aspira (AWH) have performed compared to their sector so far this year. more_horizontal

ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022

By GlobeNewsWire
April 6, 2022

ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022

MENLO PARK, Calif. and SINGAPORE, April 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biophar more_horizontal

ASLAN Pharma Kickstarts Mid-Stage Atopic Dermatitis Trial, Data Expected In 2023

By Benzinga
January 21, 2022

ASLAN Pharma Kickstarts Mid-Stage Atopic Dermatitis Trial, Data Expected In 2023

ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has screened the first patient in its Phase 2b dose-ranging study of eblasakimab (ASLAN004) in adults with more_horizontal


Search within

Pages Search Results: